TLDR
- APVO plunges 36%, stabilizing around $0.60 before 1-for-18 reverse split.
- Biotech stock reacts sharply as every 18 APVO shares convert to one share.
- APVO options, warrants, and equity plans adjust proportionally for split.
- Early sell-off hits APVO, showing weak buying and bearish trading sentiment.
- Reverse split effective Dec 29, APVO trades split-adjusted on Dec 30.
Aptevo Therapeutics Inc. (APVO) stock plummeted 36.35% to $0.5920, following a steep decline early in trading.
Aptevo Therapeutics Inc., APVO
The stock briefly touched $0.58 before stabilizing near $0.60, signaling sustained selling pressure. This sharp drop comes as the company prepares for a 1-for-18 reverse stock split effective December 29, 2025.
Reverse Split Details and Share Adjustment
The reverse split will consolidate every 18 shares of APVO into one share, reducing total shares from roughly 18 million to about 1 million. Shareholders will not receive fractional shares, but they will get cash payments for any fractions. All outstanding stock options, warrants, and restricted units will adjust proportionally to reflect the new share count.
The split will not change the stock’s trading symbol, APVO, which will continue trading on Nasdaq. Following the effective time, shares will begin trading on a split-adjusted basis at market open on December 30, 2025. The company’s par value of $0.001 per share will remain unchanged, ensuring structural consistency post-split.
Equity incentive plans will also adjust, reflecting the reverse split in their share allocations. This ensures continuity across employee and executive stock plans. The reverse split was initially approved during the company’s annual meeting on July 24, 2025.
Market Reaction and Trading Dynamics
APVO stock has shown limited recovery after the early sell-off, consolidating in the $0.58–$0.60 range. Weak buying momentum indicates bearish sentiment continues to dominate trading. The decline may reflect market anticipation of the reverse split and the potential perception of reduced liquidity post-adjustment.
Trading volume surged during the decline, highlighting intense selling pressure. Analysts note that reverse splits can create short-term volatility, which appears evident in APVO’s session. The stock’s trend remains negative, and buyers have not yet regained control.
Investors reacted swiftly to the 1-for-18 reverse split announcement, driving the stock down sharply. Market watchers expected some volatility, but the size of the drop was significant. The consolidation around $0.60 may set the stage for price stability before the split becomes effective.
Company Background and Strategic Context
APVOÂ focuses on immune-oncology therapeutics using its ADAPTIRâ„¢ and ADAPTIR-FLEXâ„¢ platform technologies. The company continues to develop clinical-stage treatments, while managing its stock structure for long-term capital strategy. The reverse split aims to improve marketability and maintain Nasdaq listing standards.
The company previously filed detailed SEC documents, including a proxy statement on July 3, 2025, explaining the reverse split rationale. Adjustments to options, warrants, and stock awards will ensure proportional equity treatment for stakeholders. APVO’s current market behavior reflects the combination of the upcoming split and broader biotech trading dynamics.
The upcoming reverse split and current stock performance highlight APVO’s strategic efforts to streamline shares. With shares trading below $1 before the split, the adjustment aligns with Nasdaq requirements. APTEVO’s market activity underscores significant structural changes ahead of the split.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
